We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite a $78 million pretax charge related to the recent recall of its Taxus drug-eluting stent, Boston Scientific last week posted record second-quarter earnings.